DRUG
Bright Minds Biosciences IncKey Statistics
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc. (DRUG) is an innovative clinical-stage biotechnology company focused on developing groundbreaking therapies for central nervous system disorders, emphasizing mental health and pain management. Utilizing its proprietary drug development platform, the firm is advancing a diverse pipeline that highlights both effectiveness and safety, in line with the rising acceptance of psychedelic treatments. With a highly experienced management team and a robust intellectual property portfolio, Bright Minds is well-positioned to leverage the increasing demand for novel mental health solutions, representing a compelling opportunity for institutional investors seeking significant growth in the evolving pharmaceutical sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -15.00% |
| Return on Assets | -10.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $8.39 |
| Price-to-Book | 3.65 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $9.79M |
| Float | $5.17M |
| % Insiders | 11.53% |
| % Institutions | 92.81% |
Historical Volatility
Volatility is currently expanding